# A Phase I/II Clinical Trial of PXD101 in Combination With Doxorubicin in Patients With Soft Tissue Sarcomas

> **NCT00878800** · PHASE1,PHASE2 · COMPLETED · sponsor: **Valerio Therapeutics** · enrollment: 41 (actual)

## Conditions studied

- Dose Escalation: Solid Tumors
- MTD: Soft Tissue Sarcomas

## Interventions

- **DRUG:** PXD101
- **DRUG:** Doxorubicin

## Key facts

- **NCT ID:** NCT00878800
- **Lead sponsor:** Valerio Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2015-07-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00878800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00878800, "A Phase I/II Clinical Trial of PXD101 in Combination With Doxorubicin in Patients With Soft Tissue Sarcomas". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00878800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*